Will the FDA approve baxdrostat for hard-to-control hypertension?

Prediction market on kalshi. If the FDA approves baxdrostat for hard-to-control hypertension for marketing before Jul 1, 2026, then the market resolves to Yes.

24h Volume: $958.42. Liquidity: $1,742.14. Resolves: 7/8/2026.